MD-Fraction combined with trastuzumab could enhance antitumor efficacy by augmenting ADCC, complement-dependent cellular cytotoxicity (CDCC), and complement-dependent cytotoxicity (CDC), suggesting a promising strategy for improving the benefits of trastuzumab in HER2-positive breast cancer 206. Here, ERBB2 is linked to breast carcinoma.